# 4. Evaluation & Benchmarking

Rigorous evaluation is arguably the hardest and most important part of bio foundation model research — a recurring theme across this entire repo.

---

### Q: How would you evaluate whether a newly pretrained protein language model is actually good, beyond just reporting its pretraining loss (e.g., masked-residue prediction accuracy)? 🟡

**Answer:**
- **Downstream task benchmarking:** evaluate the model's learned representations (via fine-tuning or as frozen features for a simple downstream model) on a diverse suite of established downstream tasks with real biological/experimental ground truth (e.g., predicting protein stability, function, or the effect of specific mutations) — pretraining loss alone doesn't guarantee these representations are actually useful for tasks practitioners care about.
- **Zero-shot evaluation on mutational effect prediction:** many protein language models are evaluated on their ability to predict the fitness effect of mutations in a zero-shot manner (see section 1), comparing the model's implicit predictions against experimentally measured mutational effect data — a widely used and relatively rigorous evaluation approach precisely because it doesn't require any task-specific fine-tuning that could otherwise mask weaknesses in the raw pretrained representations.
- **Rigorous, evolutionarily-aware held-out evaluation** (see section 3) to ensure reported performance reflects genuine generalization rather than evolutionary redundancy/leakage between pretraining and evaluation data.
- **Comparison against strong, simple baselines** — e.g., comparing against much simpler methods (like basic evolutionary conservation scores from a multiple sequence alignment, which don't require any deep learning at all) to confirm the foundation model is actually adding value beyond what a much simpler, well-established method already captures; this baseline comparison is often skipped in practice but is essential for correctly interpreting whether a sophisticated model's apparent performance gain is real and meaningful.

**Follow-ups:**
- If a new protein language model shows only marginal improvement over a much simpler evolutionary-conservation-based baseline on a specific downstream task, how would you interpret this, and would you still consider the new model valuable?

---

### Q: What is "probing," and how is it used to understand what a pretrained biological foundation model has actually learned? 🟡

**Answer:**
Probing involves training a simple, typically linear (or otherwise low-capacity) classifier/regressor on top of a pretrained model's frozen internal representations (embeddings from a specific layer) to predict some target property of interest, and using the probe's performance as a measure of how well that specific property is linearly (or simply) encoded in the model's learned representations at that layer.

This is used in bio foundation model research to investigate questions like: does a protein language model's internal representation linearly encode information about secondary structure, or solvent accessibility, or other structural properties, even though it was never explicitly trained on structural labels? A high probing accuracy for a specific property suggests the pretrained model has implicitly learned to represent that property in an easily-extractable way, providing interpretability insight into what the broad, self-supervised pretraining objective actually induced the model to learn, beyond just its aggregate downstream task performance.

Caveat: probing results should be interpreted carefully — a low linear-probing accuracy for some property doesn't necessarily mean the information isn't present in the model's representations at all, only that it isn't easily linearly extractable at the specific layer probed, and a probe's own capacity/design choices can meaningfully affect results.

**Follow-ups:**
- If a linear probe shows a certain structural property is poorly encoded at an early model layer but well encoded at a later layer, what might that suggest about how the model builds up its internal representations during processing?

---

### Q: How would you design a benchmark to evaluate multiple competing bio foundation models fairly, given that different research groups might report favorable results using their own preferred evaluation protocols? 🔴

**Answer:**
- **Use a standardized, independently-curated benchmark suite** (ideally maintained by a neutral third party or broad community consensus, similar in spirit to how established benchmark suites function in the broader ML research community) rather than relying on each model's own paper-reported numbers, which can reflect protocol choices (data splits, evaluation metrics, baseline comparisons) that happen to favor that specific model.
- **Ensure consistent, appropriately rigorous data splitting across all models being compared** (e.g., the same evolutionarily-aware held-out splits discussed in section 3, applied uniformly), since inconsistent splitting protocols between different models' original papers is a common, serious source of apples-to-oranges benchmark comparisons that can make published performance numbers non-comparable at face value.
- **Report a diverse set of tasks and metrics rather than a single aggregate score**, since different models may have genuinely different relative strengths across different task types (e.g., one model might excel at structure-related probing tasks while another excels at zero-shot mutational effect prediction), and collapsing this into a single leaderboard number can obscure genuinely useful, more nuanced comparative information.
- **Re-run models yourself under identical conditions where feasible**, rather than solely relying on cross-paper reported numbers, since subtle differences in exact evaluation implementation (which are easy to get wrong or handle inconsistently across different research groups' codebases) can meaningfully affect reported results even when the nominal benchmark task is the same.
- **Be transparent about the benchmark's own limitations and potential biases** (e.g., which biological domains or protein families are over- or under-represented in the benchmark's task suite), since a benchmark itself can favor certain modeling approaches for reasons unrelated to genuine biological usefulness.

**Follow-ups:**
- How would you handle a situation where two competing models each perform best on a different subset of your benchmark's tasks, with no clear overall winner — how would you communicate this comparison honestly rather than being forced into declaring a single "best" model?

---

### Q: Why is "downstream task performance" alone sometimes an insufficient measure of a bio foundation model's value, and what additional properties might a research team want to evaluate? 🔴

**Answer:**
Downstream task performance on a specific benchmark measures how well a model does on that specific, often narrowly-scoped task, but doesn't necessarily capture other properties that matter for a model's genuine scientific and practical value:
- **Generalization breadth:** does the model perform well across a genuinely diverse range of tasks and protein/sequence families, or does its apparent strength concentrate narrowly on tasks/families well-represented in its pretraining or evaluation data (see section 3's discussion of evolutionary redundancy)?
- **Calibration and uncertainty quantification:** does the model provide well-calibrated confidence/uncertainty estimates alongside predictions, which matters enormously for real-world decision-making (e.g., in the active-learning and prioritization contexts discussed in the AI Drug Discovery Scientist and ML Engineer (Biotech) companion repos), even if raw point-prediction accuracy looks similar to a competing model without good calibration?
- **Robustness to distribution shift:** how does the model's performance degrade when applied to sequences/data meaningfully different from its training distribution (e.g., a different organism, a poorly-represented protein family), since real-world deployment often involves exactly this kind of distribution shift?
- **Computational efficiency and practicality:** a model with marginally better benchmark performance but dramatically higher inference cost/latency may be a worse overall choice for many practical applications than a smaller, faster, slightly-less-accurate model, similar to the model right-sizing considerations discussed in the ML Engineer (Biotech) and Prompt Engineer companion repos.

**Follow-ups:**
- How would you design an evaluation specifically to assess a bio foundation model's calibration (not just raw accuracy), and why does calibration matter especially in this domain?

---

### Q: What is "benchmark saturation" or "benchmark gaming," and why is this a growing concern in bio foundation model research specifically? 🔴

**Answer:**
Benchmark saturation occurs when a field converges on optimizing performance against a small, fixed set of popular benchmarks to the point where reported improvements on those specific benchmarks no longer reliably indicate genuine, broader scientific/practical progress — sometimes because models (deliberately or inadvertently) become specifically tuned to quirks of the fixed benchmark's particular data/protocol rather than genuinely improving on the underlying scientific capability the benchmark was originally meant to measure.

This is a growing concern in bio foundation model research because: **the number of high-quality, rigorously-constructed benchmarks with real experimental ground truth is comparatively limited** (given the cost of generating experimental data, as discussed in section 1), so the field can end up repeatedly re-testing against the same handful of established benchmarks — increasing the risk that apparent progress reflects overfitting to these specific benchmarks' particular characteristics rather than genuinely improved biological understanding; and **benchmark data itself is often drawn from the same limited pool of public sequence/structure databases used for pretraining**, raising exactly the evolutionary-redundancy/leakage concerns discussed in section 3, which can make repeated benchmark improvements partly illusory if not carefully controlled for. A healthy research practice involves periodically introducing genuinely new, carefully-constructed benchmarks (ideally based on newly-generated experimental data not available during any existing model's pretraining) and being appropriately skeptical of purely incremental gains on long-saturated benchmarks.

**Follow-ups:**
- How would you evaluate whether an existing widely-used benchmark in your field has become saturated, and what would you do about it if you concluded that it had?
